Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity

Targeting mTORC1 has been thoroughly explored in cancer therapy. Following encouraging preclinical studies, mTORC1 inhibitors however failed to provide substantial benefits in cancer patients. Several resistance mechanisms have been identified including mutations of mTOR and activation of alternate...

Descripción completa

Detalles Bibliográficos
Autores principales: Faes, Seraina, Demartines, Nicolas, Dormond, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322438/
https://www.ncbi.nlm.nih.gov/pubmed/28280521
http://dx.doi.org/10.1155/2017/1726078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322438/
https://www.ncbi.nlm.nih.gov/pubmed/28280521
http://dx.doi.org/10.1155/2017/1726078

Ejemplares similares